(AOF) – GenSight Biologics (-5.89% to 0.39 euros) announces that its cash position stands at 2.2 million euros as of March 31, 2024, compared to 2.1 million euros as of December 31, 2023 The biotech specialist in innovative gene therapies for neurodegenerative diseases of the retina and central nervous system disorders warns that it does not have sufficient net working capital to meet its obligations over the next 12 months, but “only until the end of April 2024”.
Gensight says it is currently engaged in active discussions to secure funding for its activities until the 3rd quarter of 2024, when the Early Access Program (EAP) in France is expected to resume. Upon resumption of this program, the biotech estimates that its cash flow horizon will be extended until the end of the first quarter of 2025.
The company is also engaged in numerous discussions on strategic opportunities with potential partners, including a possible merger, acquisition or licensing agreement,
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
